Cervical Cancer Treatment Guidelines
Introduction to Treatment
- The standard treatment for cervical cancer stage IIIB is concurrent chemoradiation based on cisplatin, which has shown significant benefits in overall survival and local disease control, according to the American Society of Clinical Oncology 1, 2
Fundamentals of Treatment
- Concurrent chemoradiation has demonstrated an absolute benefit of 8% in 5-year survival, 9% in locoregional disease-free survival, and 7% in metastasis-free survival compared to radiation therapy alone, as recommended by the National Comprehensive Cancer Network 2
- The most commonly used chemotherapy regimen is cisplatin monotherapy at a dose of 40 mg/m² weekly during external radiation therapy, with a strength of evidence level I 2
- For patients who cannot tolerate cisplatin, alternative regimens with carboplatin or non-platinum schemes can be considered, based on level II evidence 2
Components of Treatment
Radiation Therapy
- Radiation therapy should include external radiation to cover macroscopic disease, parametria, and at-risk lymph node volumes, with a high total dose (80-90 Gy to the target) and short treatment duration (<50-55 days) to optimize outcomes, as recommended by the American College of Radiology 2, 3
- Brachytherapy is an essential component of definitive treatment, with level I evidence supporting its use 3
Concurrent Chemotherapy
- Weekly cisplatin at 40 mg/m² during external radiation therapy is the standard regimen, with level I evidence supporting its use 2
- Chemotherapy potentiates the effects of radiation and improves local control and survival, based on multiple randomized clinical trials and meta-analyses 1, 2
Quimioterapia Adyuvante
- Recent evidence suggests a significant benefit with adjuvant chemotherapy after concurrent chemoradiation, with level II evidence supporting its use 2
- A study demonstrated improved progression-free survival and overall survival with cisplatin-gemcitabine during and after radiation therapy in patients with locally advanced cervical cancer (stages IIB to IV), although this strategy still requires further research before becoming a standard treatment 2
Seguimiento
- Clinical and gynecological examination, including cervical cytology (considering changes in irradiated patients), should be performed every 3 months during the first 2 years, every 6 months during the next 3 years, and annually thereafter, as recommended by the American College of Obstetricians and Gynecologists 4
- The SCC antigen can be useful in monitoring squamous cell carcinomas if it was initially elevated, with level III evidence supporting its use 3
Advertencias y Consideraciones
- Concurrent chemoradiation increases acute toxicity, particularly gastrointestinal and hematological side effects, with level I evidence supporting this association 1
Evidence‑Based Management of Stage III Cervical Cancer
Standard Definitive Treatment
- Concurrent chemoradiation with weekly cisplatin 40 mg/m² plus high‑dose external‑beam radiation (total 80–90 Gy delivered within < 50–55 days) yields an absolute 8 % improvement in 5‑year overall survival compared with radiation alone. Level I evidence. 5, 6
- The same regimen provides a 9 % absolute gain in 5‑year locoregional disease‑free survival and a 7 % gain in 5‑year metastasis‑free survival. Level I evidence. 5, 6
Radiation Therapy Parameters
- External‑beam radiation must achieve a total dose of 80–90 Gy to macroscopic disease, parametria, and at‑risk nodal volumes, and the entire course should be completed in ≤ 55 days to optimize tumor control. Level I evidence. 5, 6
Chemotherapy Regimens
- Weekly cisplatin 40 mg/m² administered during external‑beam radiation is the standard chemotherapy component, supported by Level I evidence. 5, 6
- For patients unable to receive cisplatin (e.g., renal impairment), carboplatin‑based or other non‑platinum chemoradiation regimens are acceptable alternatives. Level I evidence. 5, 6
Adjuvant (Post‑Chemoradiation) Therapy
- Adding cisplatin‑gemcitabine both during and after radiation improves progression‑free and overall survival in stages IIB‑IV, but the data are Level II‑C; therefore, this approach should be confined to clinical‑trial settings. 5, 6